# JNJ catalysts: JOHNSON & JOHNSON PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/jnj/catalysts

> JOHNSON & JOHNSON (JNJ) has 150 upcoming catalysts. The next is the JNJ-95597528 primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | JOHNSON & JOHNSON |
| Ticker | JNJ (NYSE) |
| SEC CIK | 200406 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/jnj |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 20, 2016 | [Invokamet Xr (canagliflozin; metformin hydrochloride) FDA approval](https://sec-api.dev/pdufa/canagliflozin-metformin) | JNJ |  | completed, approved | "NDA205879 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20160920, review_priority STANDARD; sponsor_name JANSSEN PHARMS; product INVOKAMET XR (CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205879%22)) |
| September 23, 2016 | [WEZLANA® (ustekinumab) FDA approval](https://sec-api.dev/pdufa/ustekinumab) | JNJ |  | completed, approved | "BLA761044 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20160923, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product STELARA (USTEKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761044%22)) |
| October 19, 2016 | [Vermox (mebendazole) FDA approval](https://sec-api.dev/pdufa/mebendazole) | JNJ |  | completed, approved | "NDA208398 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20161019, review_priority PRIORITY; sponsor_name JANSSEN PHARMS; product VERMOX (MEBENDAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208398%22)) |
| July 13, 2017 | [Tremfya (guselkumab) FDA approval](https://sec-api.dev/pdufa/guselkumab) | JNJ |  | completed, approved | "BLA761061 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170713, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22)) |
| September 5, 2017 | [Tracleer (bosentan) FDA approval](https://sec-api.dev/pdufa/bosentan) | JNJ |  | completed, approved | "NDA209279 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20170905, review_priority STANDARD; sponsor_name ACTELION; product TRACLEER (BOSENTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209279%22)) |
| February 14, 2018 | [Erleada (apalutamide) FDA approval](https://sec-api.dev/pdufa/apalutamide) | JNJ |  | completed, approved | "NDA210951 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180214, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product ERLEADA (APALUTAMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210951%22)) |
| July 17, 2018 | [Symtuza (cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate) FDA approval](https://sec-api.dev/pdufa/cobicistat-darunavir-emtricitabine-tenofovir-alafenamide) | JNJ |  | completed, approved | "NDA210455 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20180717, review_priority STANDARD; sponsor_name JANSSEN PRODS; product SYMTUZA (COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210455%22)) |
| March 5, 2019 | [Spravato (esketamine hydrochloride) FDA approval](https://sec-api.dev/pdufa/esketamine) | JNJ |  | completed, approved | "NDA211243 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20190305, review_priority PRIORITY; sponsor_name JANSSEN PHARMS; product SPRAVATO (ESKETAMINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211243%22)) |
| April 12, 2019 | [Balversa (erdafitinib) FDA approval](https://sec-api.dev/pdufa/erdafitinib) | JNJ |  | completed, approved | "NDA212018 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190412, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product BALVERSA (ERDAFITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212018%22)) |
| December 20, 2019 | [Caplyta (lumateperone tosylate) FDA approval](https://sec-api.dev/pdufa/lumateperone) | JNJ |  | completed, approved | "NDA209500 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191220, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22)) |
| January 27, 2020 | [Invokamet Xr (canagliflozin; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/canagliflozin-metformin) | JNJ |  | completed, approved | "NDA205879 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20200127, review_priority STANDARD; sponsor_name JANSSEN PHARMS; product INVOKAMET XR (CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205879%22)) |
| March 2, 2020 | [Symtuza (cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/cobicistat-darunavir-emtricitabine-tenofovir-alafenamide) | JNJ |  | completed, approved | "NDA210455 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20200302, review_priority STANDARD; sponsor_name JANSSEN PRODS; product SYMTUZA (COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210455%22)) |
| March 10, 2020 | [Xarelto (rivaroxaban) label expansion decision](https://sec-api.dev/pdufa/rivaroxaban) | JNJ |  | completed, approved | "NDA202439 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20200310, review_priority STANDARD; sponsor_name JANSSEN PHARMS; product XARELTO (RIVAROXABAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202439%22)) |
| May 1, 2020 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) FDA approval](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20200501, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| May 27, 2020 | [Sirturo (bedaquiline fumarate) label expansion decision](https://sec-api.dev/pdufa/bedaquiline) | JNJ |  | completed, approved | "NDA204384 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20200527, review_priority PRIORITY; sponsor_name JANSSEN THERAP; product SIRTURO (BEDAQUILINE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204384%22)) |
| June 29, 2020 | [DARZALEX (daratumumab) label expansion decision](https://sec-api.dev/pdufa/daratumumab) | JNJ |  | completed, approved | "BLA761036 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20200629, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22)) |
| July 13, 2020 | [Tremfya (guselkumab) label expansion decision](https://sec-api.dev/pdufa/guselkumab) | JNJ |  | completed, approved | "BLA761061 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20200713, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22)) |
| July 31, 2020 | [Prezcobix (cobicistat; darunavir ethanolate) label expansion decision](https://sec-api.dev/pdufa/cobicistat-darunavir-ethanolate) | JNJ |  | completed, approved | "NDA205395 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20200731, review_priority STANDARD; sponsor_name JANSSEN PRODS; product PREZCOBIX (COBICISTAT; DARUNAVIR ETHANOLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205395%22)) |
| July 31, 2020 | [Spravato (esketamine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/esketamine) | JNJ |  | completed, approved | "NDA211243 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20200731, review_priority STANDARD; sponsor_name JANSSEN PHARMS; product SPRAVATO (ESKETAMINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211243%22)) |
| August 18, 2020 | [Invokana (canagliflozin) label expansion decision](https://sec-api.dev/pdufa/canagliflozin) | JNJ |  | completed, approved | "NDA204042 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20200818, review_priority STANDARD; sponsor_name JANSSEN PHARMS; product INVOKANA (CANAGLIFLOZIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204042%22)) |
| August 18, 2020 | [Invokamet Xr (canagliflozin; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/canagliflozin-metformin) | JNJ |  | completed, approved | "NDA205879 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20200818, review_priority STANDARD; sponsor_name JANSSEN PHARMS; product INVOKAMET XR (CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205879%22)) |
| August 20, 2020 | [DARZALEX (daratumumab) label expansion decision](https://sec-api.dev/pdufa/daratumumab) | JNJ |  | completed, approved | "BLA761036 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20200820, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22)) |
| September 29, 2020 | [Aria® (golimumab) label expansion decision](https://sec-api.dev/pdufa/golimumab) | JNJ |  | completed, approved | "BLA125433 SUPPL-30 (Efficacy): submission_status AP, submission_status_date 20200929, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product SIMPONI ARIA (GOLIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125433%22)) |
| November 20, 2020 | [Erleada (apalutamide) label expansion decision](https://sec-api.dev/pdufa/apalutamide) | JNJ |  | completed, approved | "NDA210951 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20201120, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product ERLEADA (APALUTAMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210951%22)) |
| January 11, 2021 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) label expansion decision](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20210111, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| January 21, 2021 | [Edurant Ped (rilpivirine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/rilpivirine) | JNJ |  | completed, approved | "NDA202022 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20210121, review_priority PRIORITY; sponsor_name JANSSEN PRODS; product EDURANT (RILPIVIRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202022%22)) |
| January 30, 2021 | [Uptravi (selexipag) label expansion decision](https://sec-api.dev/pdufa/selexipag) | JNJ |  | completed, approved | "NDA207947 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20210130, review_priority STANDARD; sponsor_name ACTELION; product UPTRAVI (SELEXIPAG)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207947%22)) |
| February 1, 2021 | [Aria® (golimumab) label expansion decision](https://sec-api.dev/pdufa/golimumab) | JNJ |  | completed, approved | "BLA125433 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20210201, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product SIMPONI ARIA (GOLIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125433%22)) |
| May 21, 2021 | [Rybrevant (amivantamab-vmjw) FDA approval](https://sec-api.dev/pdufa/amivantamab-vmjw) | JNJ |  | completed, approved | "BLA761210 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210521, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product RYBREVANT (AMIVANTAMAB-VMJW)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761210%22)) |
| July 9, 2021 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) label expansion decision](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20210709, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| July 29, 2021 | [Uptravi (selexipag) FDA approval](https://sec-api.dev/pdufa/selexipag) | JNJ |  | completed, approved | "NDA214275 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20210729, review_priority STANDARD; sponsor_name ACTELION; product UPTRAVI (SELEXIPAG)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214275%22)) |
| August 23, 2021 | [Xarelto (rivaroxaban) label expansion decision](https://sec-api.dev/pdufa/rivaroxaban) | JNJ |  | completed, approved | "NDA202439 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20210823, review_priority STANDARD; sponsor_name JANSSEN PHARMS; product XARELTO (RIVAROXABAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202439%22)) |
| August 30, 2021 | [Invega Hafyera (paliperidone palmitate) label expansion decision](https://sec-api.dev/pdufa/paliperidone-palmitate) | JNJ |  | completed, approved | "NDA207946 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20210830, review_priority STANDARD; sponsor_name JANSSEN PHARMS; product INVEGA HAFYERA (PALIPERIDONE PALMITATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207946%22)) |
| September 7, 2021 | [Erleada (apalutamide) label expansion decision](https://sec-api.dev/pdufa/apalutamide) | JNJ |  | completed, approved | "NDA210951 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20210907, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product ERLEADA (APALUTAMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210951%22)) |
| November 30, 2021 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) label expansion decision](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20211130, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| December 17, 2021 | [Caplyta (lumateperone tosylate) label expansion decision](https://sec-api.dev/pdufa/lumateperone) | JNJ |  | completed, approved | "NDA209500 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20211217, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22)) |
| December 20, 2021 | [Xarelto (rivaroxaban) FDA approval](https://sec-api.dev/pdufa/rivaroxaban) | JNJ |  | completed, approved | "NDA215859 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20211220, review_priority PRIORITY; sponsor_name JANSSEN PHARMS; product XARELTO (RIVAROXABAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215859%22)) |
| January 13, 2022 | [Topamax Sprinkle (topiramate) label expansion decision](https://sec-api.dev/pdufa/topiramate) | JNJ |  | completed, approved | "NDA020844 SUPPL-53 (Efficacy): submission_status AP, submission_status_date 20220113, review_priority STANDARD; sponsor_name JANSSEN PHARMS; product TOPAMAX SPRINKLE (TOPIRAMATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020844%22)) |
| January 31, 2022 | [Edurant Ped (rilpivirine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/rilpivirine) | JNJ |  | completed, approved | "NDA202022 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20220131, review_priority STANDARD; sponsor_name JANSSEN PRODS; product EDURANT (RILPIVIRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202022%22)) |
| February 25, 2022 | [Acuvue Theravision With Ketotifen (ketotifen fumarate) FDA approval](https://sec-api.dev/pdufa/ketotifen) | JNJ |  | completed, approved | "NDA022388 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20220225, review_priority STANDARD; sponsor_name JOHNSON JOHNSON VISN; product ACUVUE THERAVISION WITH KETOTIFEN (KETOTIFEN FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022388%22)) |
| March 4, 2022 | [DARZALEX (daratumumab) label expansion decision](https://sec-api.dev/pdufa/daratumumab) | JNJ |  | completed, approved | "BLA761036 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20220304, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22)) |
| March 29, 2022 | [Edurant Ped (rilpivirine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/rilpivirine) | JNJ |  | completed, approved | "NDA202022 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20220329, review_priority PRIORITY; sponsor_name JANSSEN PRODS; product EDURANT (RILPIVIRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202022%22)) |
| October 25, 2022 | [Tecvayli (teclistamab-cqyv) FDA approval](https://sec-api.dev/pdufa/teclistamab-cqyv) | JNJ |  | completed, approved | "Tecvayli \| teclistamab-cqyv \| 10/25/2022 \| To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| November 4, 2022 | [Rybrevant (amivantamab-vmjw) label expansion decision](https://sec-api.dev/pdufa/amivantamab-vmjw) | JNJ |  | completed, approved | "BLA761210 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20221104, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product RYBREVANT (AMIVANTAMAB-VMJW)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761210%22)) |
| January 19, 2023 | [DARZALEX (daratumumab) label expansion decision](https://sec-api.dev/pdufa/daratumumab) | JNJ |  | completed, approved | "BLA761036 SUPPL-44 (Efficacy): submission_status AP, submission_status_date 20230119, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22)) |
| August 9, 2023 | [Talvey (talquetamab-tgvs) FDA approval](https://sec-api.dev/pdufa/talquetamab-tgvs) | JNJ |  | completed, approved | "Talvey \| talquetamab-tgvs \| 8/9/2023 \| To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapiesDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| August 11, 2023 | [Akeega (abiraterone acetate; niraparib tosylate) FDA approval](https://sec-api.dev/pdufa/abiraterone-niraparib) | JNJ |  | completed, approved | "NDA216793 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20230811, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product AKEEGA (ABIRATERONE ACETATE; NIRAPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216793%22)) |
| December 19, 2023 | [Erleada (apalutamide) label expansion decision](https://sec-api.dev/pdufa/apalutamide) | JNJ |  | completed, approved | "NDA210951 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20231219, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product ERLEADA (APALUTAMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210951%22)) |
| January 19, 2024 | [Balversa (erdafitinib) label expansion decision](https://sec-api.dev/pdufa/erdafitinib) | JNJ |  | completed, approved | "NDA212018 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20240119, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product BALVERSA (ERDAFITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212018%22)) |
| February 20, 2024 | [Tecvayli (teclistamab-cqyv) label expansion decision](https://sec-api.dev/pdufa/teclistamab-cqyv) | JNJ |  | completed, approved | "BLA761291 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20240220, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TECVAYLI (TECLISTAMAB-CQYV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761291%22)) |
| March 1, 2024 | [Rybrevant (amivantamab-vmjw) label expansion decision](https://sec-api.dev/pdufa/amivantamab-vmjw) | JNJ |  | completed, approved | "BLA761210 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20240301, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product RYBREVANT (AMIVANTAMAB-VMJW)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761210%22)) |
| March 15, 2024 | [CARVYKTI (ciltacabtagene autoleucel) FDA advisory committee meeting](https://sec-api.dev/pdufa/ciltacabtagene-autoleucel) | JNJ |  | completed, positive | "During the morning session, the Committee will discuss supplemental biologics license application (sBLA) 125746.74 for CARVYKTI (ciltacabtagene autoleucel), suspension for intravenous infusion, submitted by Janssen Biotech, Inc. The proposed indication for this product is for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior line of therapy, including a proteasome inhibitor, and an immunomodulatory agent, and are refractory to lenalidomide." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-15-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-03152024)) |
| March 15, 2024 | [Edurant Ped (rilpivirine hydrochloride) FDA approval](https://sec-api.dev/pdufa/rilpivirine) | JNJ |  | completed, approved | "NDA219016 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240315, review_priority PRIORITY; sponsor_name JANSSEN PRODS; product EDURANT PED (RILPIVIRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219016%22)) |
| March 15, 2024 | [Edurant Ped (rilpivirine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/rilpivirine) | JNJ |  | completed, approved | "NDA202022 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20240315, review_priority PRIORITY; sponsor_name JANSSEN PRODS; product EDURANT (RILPIVIRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202022%22)) |
| March 22, 2024 | [Opsynvi (macitentan; tadalafil) FDA approval](https://sec-api.dev/pdufa/macitentan-tadalafil) | JNJ |  | completed, approved | "NDA218490 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20240322, review_priority STANDARD; sponsor_name ACTELION; product OPSYNVI (MACITENTAN; TADALAFIL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218490%22)) |
| June 21, 2024 | [Sirturo (bedaquiline fumarate) label expansion decision](https://sec-api.dev/pdufa/bedaquiline) | JNJ |  | completed, approved | "NDA204384 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20240621, review_priority STANDARD; sponsor_name JANSSEN THERAP; product SIRTURO (BEDAQUILINE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204384%22)) |
| July 30, 2024 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) label expansion decision](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20240730, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| July 31, 2024 | [DARZALEX (daratumumab) label expansion decision](https://sec-api.dev/pdufa/daratumumab) | JNJ |  | completed, approved | "BLA761036 SUPPL-50 (Efficacy): submission_status AP, submission_status_date 20240731, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22)) |
| August 19, 2024 | [Rybrevant (amivantamab-vmjw) label expansion decision](https://sec-api.dev/pdufa/amivantamab-vmjw) | JNJ |  | completed, approved | "BLA761210 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240819, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product RYBREVANT (AMIVANTAMAB-VMJW)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761210%22)) |
| August 19, 2024 | [Lazcluze (lazertinib mesylate) FDA approval](https://sec-api.dev/pdufa/lazertinib) | JNJ | To treat non-small cell lung cancer | completed, approved | "Lazcluze \| lazertinib \| 8/19/2024 \| To treat non-small cell lung cancerDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| September 11, 2024 | [Tremfya (guselkumab) label expansion decision](https://sec-api.dev/pdufa/guselkumab) | JNJ |  | completed, approved | "BLA761061 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20240911, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22)) |
| September 19, 2024 | [Rybrevant (amivantamab-vmjw) label expansion decision](https://sec-api.dev/pdufa/amivantamab-vmjw) | JNJ |  | completed, approved | "BLA761210 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20240919, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product RYBREVANT (AMIVANTAMAB-VMJW)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761210%22)) |
| November 22, 2024 | [Tecvayli (teclistamab-cqyv) label expansion decision](https://sec-api.dev/pdufa/teclistamab-cqyv) | JNJ |  | completed, approved | "BLA761291 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20241122, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TECVAYLI (TECLISTAMAB-CQYV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761291%22)) |
| December 13, 2024 | [Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) complete response letter (CRL)](https://sec-api.dev/pdufa/amivantamab-and-hyaluronidase-lpuj) | JNJ |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761433_20241213.pdf%22)) |
| December 18, 2024 | [Invokana (canagliflozin) label expansion decision](https://sec-api.dev/pdufa/canagliflozin) | JNJ |  | completed, approved | "NDA204042 SUPPL-43 (Efficacy): submission_status AP, submission_status_date 20241218, review_priority PRIORITY; sponsor_name JANSSEN PHARMS; product INVOKANA (CANAGLIFLOZIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204042%22)) |
| December 18, 2024 | [Invokamet Xr (canagliflozin; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/canagliflozin-metformin) | JNJ |  | completed, approved | "NDA205879 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20241218, review_priority PRIORITY; sponsor_name JANSSEN PHARMS; product INVOKAMET XR (CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205879%22)) |
| January 17, 2025 | [Spravato (esketamine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/esketamine) | JNJ |  | completed, approved | "NDA211243 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20250117, review_priority PRIORITY; sponsor_name JANSSEN PHARMS; product SPRAVATO (ESKETAMINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211243%22)) |
| January 23, 2025 | [DARZALEX (daratumumab) label expansion decision](https://sec-api.dev/pdufa/daratumumab) | JNJ |  | completed, approved | "BLA761036 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20250123, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22)) |
| February 28, 2025 | [Opsumit (macitentan) label expansion decision](https://sec-api.dev/pdufa/macitentan) | JNJ |  | completed, approved | "NDA204410 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20250228, review_priority PRIORITY; sponsor_name ACTELION; product OPSUMIT (MACITENTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204410%22)) |
| March 20, 2025 | [Tremfya (guselkumab) label expansion decision](https://sec-api.dev/pdufa/guselkumab) | JNJ |  | completed, approved | "BLA761061 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20250320, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22)) |
| March 21, 2025 | [Prezcobix (cobicistat; darunavir ethanolate) label expansion decision](https://sec-api.dev/pdufa/cobicistat-darunavir-ethanolate) | JNJ |  | completed, approved | "NDA205395 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20250321, review_priority STANDARD; sponsor_name JANSSEN PRODS; product PREZCOBIX (COBICISTAT; DARUNAVIR ETHANOLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205395%22)) |
| April 10, 2025 | [DARZALEX (daratumumab) label expansion decision](https://sec-api.dev/pdufa/daratumumab) | JNJ |  | completed, approved | "BLA761036 SUPPL-54 (Efficacy): submission_status AP, submission_status_date 20250410, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22)) |
| April 29, 2025 | [Imaavy (nipocalimab-aahu) FDA approval](https://sec-api.dev/pdufa/nipocalimab-aahu) | JNJ | To treat generalized myasthenia gravis | completed, approved | "Imaavy \| nipocalimab-aahu \| 4/29/2025 \| To treat generalized myasthenia gravisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| May 8, 2025 | [Ustekinumab dose based on bsa and body weight primary completion](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) | JNJ | Colitis, Ulcerative | completed | "NCT04630028 (A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-10-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04630028)) |
| May 15, 2025 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Colitis, Ulcerative | completed | "NCT05242484 (A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05242484)) |
| May 20, 2025 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) FDA advisory committee meeting](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed | "On the afternoon of May 20, 2025, the Committee will discuss sBLA 761145/S-029, for DARZALEX FASPRO (daratumumab and hyaluronidase) injection, for subcutaneous use, submitted by Janssen Biotech, Inc. The proposed indication (use) is as monotherapy for the treatment of adult patients with high-risk smoldering multiple myeloma (SMM)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025)) |
| May 23, 2025 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn's Disease | completed | "NCT05242471 (A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-23 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05242471)) |
| May 30, 2025 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Plaque Psoriasis; Scalp Psoriasis | completed | "NCT05272150 (Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-06-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05272150)) |
| July 3, 2025 | [TAR-200 primary completion](https://sec-api.dev/pdufa/tar-200) | JNJ | Urinary Bladder Neoplasms | completed | "NCT04640623 (A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-07-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04640623)) |
| July 14, 2025 | [Pipe-307 dose a primary completion](https://sec-api.dev/pdufa/pipe-307) | JNJ | Relapsing Remitting Multiple Sclerosis | completed | "NCT06083753 (Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-14 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06083753)) |
| July 16, 2025 | [FASPRO (daratumumab-hyaluronidase) FDA advisory committee meeting](https://sec-api.dev/pdufa/daratumumab-hyaluronidase) | JNJ |  | completed | "U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/200406/000020040625000170/a2025q2exhibit991.htm)) |
| July 28, 2025 | [Sirturo (bedaquiline fumarate) label expansion decision](https://sec-api.dev/pdufa/bedaquiline) | JNJ |  | completed, approved | "NDA204384 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20250728, review_priority PRIORITY; sponsor_name JANSSEN THERAP; product SIRTURO (BEDAQUILINE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204384%22)) |
| August 1, 2025 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | completed | "NCT05083169 (A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-01 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05083169)) |
| August 14, 2025 | [Rybrevant (amivantamab-vmjw) label expansion decision](https://sec-api.dev/pdufa/amivantamab-vmjw) | JNJ |  | completed, approved | "BLA761210 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20250814, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product RYBREVANT (AMIVANTAMAB-VMJW)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761210%22)) |
| August 14, 2025 | [Lazcluze (lazertinib mesylate) label expansion decision](https://sec-api.dev/pdufa/lazertinib) | JNJ |  | completed, approved | "NDA219008 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250814, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product LAZCLUZE (LAZERTINIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219008%22)) |
| August 27, 2025 | [Expec9v primary completion](https://sec-api.dev/pdufa/expec9v) | JNJ | Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | completed | "NCT04899336 (A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-27 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04899336)) |
| September 4, 2025 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myositis | completed | "NCT05379634 (A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-04 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05379634)) |
| September 9, 2025 | [Gemzar (gemcitabine) FDA approval](https://sec-api.dev/pdufa/gemcitabine) | JNJ |  | completed, approved | "NDA219683 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250909, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product INLEXZO (GEMCITABINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219683%22)) |
| September 19, 2025 | [Tremfya (guselkumab) label expansion decision](https://sec-api.dev/pdufa/guselkumab) | JNJ |  | completed, approved | "BLA761061 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20250919, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22)) |
| October 7, 2025 | [Opsumit (macitentan) primary completion](https://sec-api.dev/pdufa/macitentan) | JNJ | Pulmonary Arterial Hypertension | completed | "NCT04273945 (Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-07 (ACTUAL); Lead Sponsor Actelion." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04273945)) |
| October 13, 2025 | [TECVAYLI (teclistamab) primary completion](https://sec-api.dev/pdufa/teclistamab) | JNJ | Multiple Myeloma | completed | "NCT05572515 (A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05572515)) |
| October 14, 2025 | [JOHNSON & JOHNSON earnings report](https://sec-api.dev/companies/jnj/catalysts) | JNJ |  | completed | "In a separate press release issued today, Johnson & Johnson announced its third-quarter results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/a2025q3exhibit993.htm)) |
| October 17, 2025 | [JNJ-63733657 primary completion](https://sec-api.dev/pdufa/jnj-63733657) | JNJ | Alzheimer Disease; Cognitive Dysfunction; Dementia | withdrawn | "NCT04619420 (A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-17 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-11-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04619420)) |
| October 28, 2025 | [Lenrispodun primary completion](https://sec-api.dev/pdufa/lenrispodun) | JNJ | Parkinson Disease | completed | "NCT05766813 (Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05766813)) |
| November 5, 2025 | [Caplyta (lumateperone tosylate) label expansion decision](https://sec-api.dev/pdufa/lumateperone) | JNJ |  | completed, approved | "NDA209500 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20251105, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22)) |
| November 6, 2025 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) label expansion decision](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20251106, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| November 17, 2025 | [WEZLANA® (ustekinumab) primary completion](https://sec-api.dev/pdufa/ustekinumab) | JNJ | Plaque Psoriasis | completed | "NCT06934226 (A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-17 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06934226)) |
| November 19, 2025 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) label expansion decision](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| December 12, 2025 | [Akeega (abiraterone acetate; niraparib tosylate) label expansion decision](https://sec-api.dev/pdufa/abiraterone-niraparib) | JNJ |  | completed, approved | "NDA216793 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251212, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product AKEEGA (ABIRATERONE ACETATE; NIRAPARIB TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216793%22)) |
| December 17, 2025 | [Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) FDA approval](https://sec-api.dev/pdufa/amivantamab-and-hyaluronidase-lpuj) | JNJ |  | completed, approved | "BLA761433 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20251217, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761433%22)) |
| January 12, 2026 | [WEZLANA® (ustekinumab) primary completion](https://sec-api.dev/pdufa/ustekinumab) | JNJ | Arthritis, Juvenile | completed | "NCT05083182 (A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05083182)) |
| January 27, 2026 | [Darzalex Faspro (daratumumab and hyaluronidase-fihj) label expansion decision](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj) | JNJ |  | completed, approved | "BLA761145 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20260127, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22)) |
| February 4, 2026 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Amyloidosis | completed | "NCT05250973 (A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05250973)) |
| February 6, 2026 | [Milvexian primary completion](https://sec-api.dev/pdufa/milvexian) | JNJ | Acute Coronary Syndrome | completed | "NCT05754957 (A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-06 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05754957)) |
| February 13, 2026 | [Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) FDA approval](https://sec-api.dev/pdufa/amivantamab-and-hyaluronidase-lpuj) | JNJ |  | completed, approved | "BLA761484 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260213, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761484%22)) |
| February 23, 2026 | [JNJ-81201887 primary completion](https://sec-api.dev/pdufa/jnj-81201887) | JNJ | Geographic Atrophy | completed | "NCT05811351 (A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05811351)) |
| February 24, 2026 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Bipolar Disorder, Manic | completed | "NCT06462586 (Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-24 (ACTUAL); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06462586)) |
| February 27, 2026 | [Prezcobix (cobicistat; darunavir and cobicistat; darunavir ethanolate) FDA approval](https://sec-api.dev/pdufa/cobicistat-darunavir-and-cobicistat-darunavir-ethanolate) | JNJ |  | completed, approved | "NDA220092 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20260227, review_priority STANDARD; sponsor_name JANSSEN PRODS; product PREZCOBIX (COBICISTAT; DARUNAVIR AND COBICISTAT; DARUNAVIR ETHANOLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220092%22)) |
| February 27, 2026 | [Prezcobix (cobicistat; darunavir ethanolate) label expansion decision](https://sec-api.dev/pdufa/cobicistat-darunavir-ethanolate) | JNJ |  | completed, approved | "NDA205395 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20260227, review_priority STANDARD; sponsor_name JANSSEN PRODS; product PREZCOBIX (COBICISTAT; DARUNAVIR ETHANOLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205395%22)) |
| March 5, 2026 | [Tecvayli (teclistamab-cqyv) label expansion decision](https://sec-api.dev/pdufa/teclistamab-cqyv) | JNJ |  | completed, approved | "BLA761291 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260305, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product TECVAYLI (TECLISTAMAB-CQYV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761291%22)) |
| March 17, 2026 | [ICOTYDE (icotrokinra) FDA approval](https://sec-api.dev/pdufa/icotrokinra) | JNJ |  | completed, approved | "Icotyde \| icotrokinra \| 3/17/2026 \| To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| March 26, 2026 | [JNJ-95475939 primary completion](https://sec-api.dev/pdufa/jnj-95475939) | JNJ | Dermatitis, Atopic | withdrawn | "NCT06881251 (A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-03-26 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06881251)) |
| April 1, 2026 | [Talquetamab primary completion](https://sec-api.dev/pdufa/talquetamab) | JNJ | Multiple Myeloma | completed | "NCT06208150 (A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-01 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06208150)) |
| April 14, 2026 | [FASPRO (daratumumab-hyaluronidase) FDA approval](https://sec-api.dev/pdufa/daratumumab-hyaluronidase) | JNJ |  | completed, approved | "Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI plus DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/a2026q1exhibit991.htm)) |
| April 15, 2026 | [WEZLANA® (ustekinumab) label expansion decision](https://sec-api.dev/pdufa/ustekinumab) | JNJ |  | completed, approved | "BLA761044 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20260415, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product STELARA (USTEKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761044%22)) |
| April 24, 2026 | [Caplyta (lumateperone tosylate) label expansion decision](https://sec-api.dev/pdufa/lumateperone) | JNJ |  | completed, approved | "NDA209500 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20260424, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22)) |
| May 15, 2026 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Bipolar Disorder, Manic | completed | "NCT06462612 (Study of Lumateperone in the Treatment of Patients With Bipolar Mania): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-15 (ACTUAL); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06462612)) |
| May 23, 2026 | [Uptravi (selexipag) label expansion decision](https://sec-api.dev/pdufa/selexipag) | JNJ |  | completed, approved | "NDA207947 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20260523, review_priority PRIORITY; sponsor_name ACTELION; product UPTRAVI (SELEXIPAG)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207947%22)) |
| May 25, 2026 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Arthritis, Psoriatic | completed | "NCT06878404 (A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-25 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06878404)) |
| May 28, 2026 | [Tremfya (guselkumab) label expansion decision](https://sec-api.dev/pdufa/guselkumab) | JNJ |  | completed, approved | "BLA761061 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20260528, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product TREMFYA (GUSELKUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761061%22)) |
| June 24, 2026 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Plaque Psoriasis; Scalp Psoriasis | completed | "NCT05272150 (Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-06-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05272150?tab=results)) |
| June 25, 2026 | [JNJ-89495120 primary completion](https://sec-api.dev/pdufa/jnj-89495120) | JNJ | Depressive Disorder, Major | completed | "NCT06785012 (A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-25 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06785012)) |
| July 29, 2026 | [TAR-200 topline data readout](https://sec-api.dev/pdufa/tar-200) | JNJ | Urinary Bladder Neoplasms | completed | "NCT04640623 (A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-07-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04640623?tab=results)) |
| August 18, 2026 | [Edurant Ped (rilpivirine hydrochloride) primary completion](https://sec-api.dev/pdufa/rilpivirine) | JNJ | Human Immunodeficiency Virus Type 1 | completed | "NCT02494986 (A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-18 (ACTUAL); Lead Sponsor Janssen Sciences Ireland UC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02494986)) |
| Aug to Nov 2026 | [Edurant Ped (rilpivirine hydrochloride) topline data readout](https://sec-api.dev/pdufa/rilpivirine) | JNJ | Human Immunodeficiency Virus Type 1 | scheduled | "NCT02494986 (A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-18 (ACTUAL); Lead Sponsor Janssen Sciences Ireland UC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02494986)) |
| August 24, 2026 | [Imaavy (nipocalimab-aahu) label expansion decision](https://sec-api.dev/pdufa/nipocalimab-aahu) | JNJ |  | completed, approved | "BLA761430 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20260824, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product IMAAVY (NIPOCALIMAB-AAHU)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761430%22)) |
| August 28, 2026 | [WEZLANA® (ustekinumab) label expansion decision](https://sec-api.dev/pdufa/ustekinumab) | JNJ |  | completed, approved | "BLA761044 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20260828, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product STELARA (USTEKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761044%22)) |
| September 28, 2026 | [Expec9v topline data readout](https://sec-api.dev/pdufa/expec9v) | JNJ | Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | completed | "NCT04899336 (A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-27 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04899336?tab=results)) |
| Oct 2026 to Jan 2027 | [Milvexian topline data readout](https://sec-api.dev/pdufa/milvexian) | JNJ | Ischemic Stroke; Ischemic Attack, Transient | scheduled | "NCT05702034 (A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05702034)) |
| Oct 2026 to Jan 2027 | [Erleada (apalutamide) topline data readout](https://sec-api.dev/pdufa/apalutamide) | JNJ | Metastatic Castrate-sensitive Prostate Cancer | scheduled | "NCT05884398 (A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05884398)) |
| October 2026 | [Erleada (apalutamide) primary completion](https://sec-api.dev/pdufa/apalutamide) | JNJ | Metastatic Castrate-sensitive Prostate Cancer | delayed | "NCT05884398 (A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05884398)) |
| October 2026 | [Milvexian primary completion](https://sec-api.dev/pdufa/milvexian) | JNJ | Ischemic Stroke; Ischemic Attack, Transient | delayed | "NCT05702034 (A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05702034)) |
| October 20, 2026 | [Ustekinumab dose based on bsa and body weight topline data readout](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) | JNJ | Colitis, Ulcerative | completed | "NCT04630028 (A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-10-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04630028?tab=results)) |
| Nov 2026 to Feb 2027 | [JNJ-95597528 topline data readout](https://sec-api.dev/pdufa/jnj-95597528) | JNJ | Dermatitis, Atopic | scheduled | "NCT07230860 (A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07230860)) |
| November 5, 2026 | [Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) label expansion decision](https://sec-api.dev/pdufa/amivantamab-and-hyaluronidase-lpuj) | JNJ |  | completed, approved | "BLA761433 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20261105, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761433%22)) |
| November 2026 | [JNJ-95597528 primary completion](https://sec-api.dev/pdufa/jnj-95597528) | JNJ | Dermatitis, Atopic | scheduled | "NCT07230860 (A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07230860)) |
| Dec 2026 to Mar 2027 | [Imbruvica (ibrutinib) topline data readout](https://sec-api.dev/pdufa/ibrutinib) | JNJ | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma | scheduled | "NCT01804686 (A Long-term Extension Study of PCI-32765 (Ibrutinib)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01804686)) |
| December 2026 | [Erleada (apalutamide) primary completion](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03767244)) |
| Dec 2026 to Mar 2027 | [Erleada (apalutamide) topline data readout](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03767244)) |
| Dec 2026 to Mar 2027 | [Gemzar (gemcitabine) topline data readout](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Urinary Bladder Neoplasms | scheduled | "NCT04658862 (A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04658862)) |
| Dec 2026 to Mar 2027 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | scheduled | "NCT05327114 (Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05327114)) |
| Dec 2026 to Mar 2027 | [Milvexian topline data readout](https://sec-api.dev/pdufa/milvexian) | JNJ | Atrial Fibrillation | scheduled | "NCT05757869 (A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05757869)) |
| Dec 2026 to Mar 2027 | [JNJ-64042056 topline data readout](https://sec-api.dev/pdufa/jnj-64042056) | JNJ | Alzheimer Disease | scheduled | "NCT06544616 (A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-22 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544616)) |
| Dec 2026 to Mar 2027 | [Seltorexant topline data readout](https://sec-api.dev/pdufa/seltorexant) | JNJ | Depressive Disorder, Major | scheduled | "NCT06559306 (Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06559306)) |
| December 2026 | [Milvexian primary completion](https://sec-api.dev/pdufa/milvexian) | JNJ | Atrial Fibrillation | scheduled | "NCT05757869 (A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05757869)) |
| December 2026 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | scheduled | "NCT05327114 (Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05327114)) |
| December 2026 | [JNJ-64042056 primary completion](https://sec-api.dev/pdufa/jnj-64042056) | JNJ | Alzheimer Disease | scheduled | "NCT06544616 (A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-22 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544616)) |
| December 2026 | [Gemzar (gemcitabine) primary completion](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Urinary Bladder Neoplasms | scheduled | "NCT04658862 (A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04658862)) |
| December 2026 | [Seltorexant primary completion](https://sec-api.dev/pdufa/seltorexant) | JNJ | Depressive Disorder, Major | scheduled | "NCT06559306 (Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06559306)) |
| December 2026 | [Imbruvica (ibrutinib) primary completion](https://sec-api.dev/pdufa/ibrutinib) | JNJ | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma | scheduled | "NCT01804686 (A Long-term Extension Study of PCI-32765 (Ibrutinib)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01804686)) |
| Jan to Apr 2027 | [Opsumit (macitentan) topline data readout](https://sec-api.dev/pdufa/macitentan) | JNJ | Hypertension, Pulmonary | scheduled | "NCT05179876 (A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Actelion." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05179876)) |
| January 2027 | [Opsumit (macitentan) primary completion](https://sec-api.dev/pdufa/macitentan) | JNJ | Hypertension, Pulmonary | scheduled | "NCT05179876 (A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Actelion." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05179876)) |
| Feb to May 2027 | [DARZALEX (daratumumab) topline data readout](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT04133636 (A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04133636)) |
| Feb to May 2027 | [Guselkumab subcutaneous topline data readout](https://sec-api.dev/pdufa/guselkumab-subcutaneous) | JNJ | Colitis, Ulcerative | scheduled | "NCT06260163 (A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260163)) |
| Feb to May 2027 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Sjogrens Syndrome | scheduled | "NCT06741969 (Nipocalimab in Moderate to Severe Sjogren's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-04 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741969)) |
| Feb to May 2027 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Arthritis, Psoriatic | scheduled | "NCT06807424 (A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807424)) |
| February 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Sjogrens Syndrome | scheduled | "NCT06741969 (Nipocalimab in Moderate to Severe Sjogren's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-04 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741969)) |
| February 2027 | [Guselkumab subcutaneous primary completion](https://sec-api.dev/pdufa/guselkumab-subcutaneous) | JNJ | Colitis, Ulcerative | scheduled | "NCT06260163 (A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260163)) |
| February 2027 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Arthritis, Psoriatic | scheduled | "NCT06807424 (A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807424)) |
| February 2027 | [Bedaquiline (tmc207) primary completion](https://sec-api.dev/pdufa/bedaquiline-tmc207) | JNJ | Tuberculosis, Multidrug-Resistant | delayed | "NCT02354014 (Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB): Overall Status SUSPENDED; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02354014)) |
| February 2027 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT04133636 (A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04133636)) |
| Mar to Jun 2027 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Fistulizing Crohns Disease; Perianal Crohns Disease | scheduled | "NCT05347095 (A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Janssen-Cilag Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05347095)) |
| Mar to Jun 2027 | [Iti-1284 10 mg topline data readout](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT06480383 (Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06480383)) |
| March 2027 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT06480383 (Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06480383)) |
| March 2027 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Fistulizing Crohns Disease; Perianal Crohns Disease | scheduled | "NCT05347095 (A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-25 (ESTIMATED); Lead Sponsor Janssen-Cilag Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05347095)) |
| Apr to Jul 2027 | [Caplyta (lumateperone tosylate) topline data readout](https://sec-api.dev/pdufa/lumateperone) | JNJ | Major Depressive Disorder | scheduled | "NCT05850689 (Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05850689)) |
| April 2027 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Major Depressive Disorder | scheduled | "NCT05850689 (Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05850689)) |
| May to Aug 2027 | [Lazcluze (lazertinib mesylate) topline data readout](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06120140 (Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06120140)) |
| May 2027 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06120140 (Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06120140)) |
| Jun to Sep 2027 | [Talquetamab topline data readout](https://sec-api.dev/pdufa/talquetamab) | JNJ | Hematological Malignancies | scheduled | "NCT04634552 (A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04634552)) |
| Jun to Sep 2027 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myasthenia Gravis | scheduled | "NCT05265273 (A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05265273)) |
| Jun to Sep 2027 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn's Disease | scheduled | "NCT06408935 (Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-08 (ESTIMATED); Lead Sponsor Janssen-Cilag Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06408935)) |
| Jun to Sep 2027 | [Caplyta (lumateperone tosylate) topline data readout](https://sec-api.dev/pdufa/lumateperone) | JNJ | Irritability Associated With Autism Spectrum Disorder | scheduled | "NCT06690398 (Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06690398)) |
| Jun to Sep 2027 | [Caplyta (lumateperone tosylate) topline data readout](https://sec-api.dev/pdufa/lumateperone) | JNJ | Irritability Associated With Autism Spectrum Disorder | scheduled | "NCT06706674 (Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06706674)) |
| Jun to Sep 2027 | [JNJ-79635322 topline data readout](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07266441 (A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266441)) |
| Jun to Sep 2027 | [JNJ-88545223 topline data readout](https://sec-api.dev/pdufa/jnj-88545223) | JNJ | Arthritis, Psoriatic | scheduled | "NCT07321873 (A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07321873)) |
| June 2027 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn's Disease | scheduled | "NCT06408935 (Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-08 (ESTIMATED); Lead Sponsor Janssen-Cilag Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06408935)) |
| June 2027 | [JNJ-79635322 primary completion](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07266441 (A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266441)) |
| June 2027 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Irritability Associated With Autism Spectrum Disorder | scheduled | "NCT06690398 (Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06690398)) |
| June 2027 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Irritability Associated With Autism Spectrum Disorder | scheduled | "NCT06706674 (Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06706674)) |
| June 2027 | [JNJ-88545223 primary completion](https://sec-api.dev/pdufa/jnj-88545223) | JNJ | Arthritis, Psoriatic | scheduled | "NCT07321873 (A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07321873)) |
| June 2027 | [Talquetamab primary completion](https://sec-api.dev/pdufa/talquetamab) | JNJ | Hematological Malignancies | scheduled | "NCT04634552 (A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04634552)) |
| June 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myasthenia Gravis | scheduled | "NCT05265273 (A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05265273)) |
| Jul to Oct 2027 | [DARZALEX (daratumumab) topline data readout](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT05455320 (A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05455320)) |
| July 2027 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT05455320 (A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05455320)) |
| Aug to Nov 2027 | [Lazcluze (lazertinib mesylate) topline data readout](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-small-Cell Lung | scheduled | "NCT05498428 (A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05498428)) |
| Aug to Nov 2027 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Hemolytic Disease of the Fetus and Newborn | scheduled | "NCT05912517 (A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-05 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05912517)) |
| Aug to Nov 2027 | [Cilta-cel topline data readout](https://sec-api.dev/pdufa/cilta-cel) | JNJ | Multiple Myeloma | scheduled | "NCT06550895 (A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06550895)) |
| August 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Hemolytic Disease of the Fetus and Newborn | scheduled | "NCT05912517 (A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-05 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05912517)) |
| August 2027 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-small-Cell Lung | scheduled | "NCT05498428 (A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05498428)) |
| August 2027 | [Cilta-cel primary completion](https://sec-api.dev/pdufa/cilta-cel) | JNJ | Multiple Myeloma | scheduled | "NCT06550895 (A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-26 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06550895)) |
| Sep to Dec 2027 | [WEZLANA® (ustekinumab) topline data readout](https://sec-api.dev/pdufa/ustekinumab) | JNJ | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic | scheduled | "NCT05092269 (A Long-term Extension Study of Ustekinumab in Pediatric Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-29 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05092269)) |
| Sep to Dec 2027 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myasthenia Gravis | scheduled | "NCT07217587 (Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217587)) |
| September 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myasthenia Gravis | scheduled | "NCT07217587 (Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217587)) |
| September 2027 | [WEZLANA® (ustekinumab) primary completion](https://sec-api.dev/pdufa/ustekinumab) | JNJ | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic | scheduled | "NCT05092269 (A Long-term Extension Study of Ustekinumab in Pediatric Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-29 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05092269)) |
| Oct 2027 to Jan 2028 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn's Disease | scheduled | "NCT05923073 (A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-27 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05923073)) |
| Oct 2027 to Jan 2028 | [Iti-1284 10 mg topline data readout](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT06701903 (Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-14 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701903)) |
| October 2027 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT06701903 (Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-14 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701903)) |
| October 2027 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn's Disease | scheduled | "NCT05923073 (A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-27 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05923073)) |
| Nov 2027 to Feb 2028 | [Pasritamig topline data readout](https://sec-api.dev/pdufa/pasritamig) | JNJ | Prostatic Neoplasms, Castration-Resistant | scheduled | "NCT07225946 (A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225946)) |
| November 2027 | [Pasritamig primary completion](https://sec-api.dev/pdufa/pasritamig) | JNJ | Prostatic Neoplasms, Castration-Resistant | scheduled | "NCT07225946 (A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225946)) |
| Dec 2027 to Mar 2028 | [Imbruvica (ibrutinib) topline data readout](https://sec-api.dev/pdufa/ibrutinib) | JNJ | Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Lymphoma | scheduled | "NCT05963074 (A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05963074)) |
| Dec 2027 to Mar 2028 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Thrombocytopenia, Neonatal Alloimmune | scheduled | "NCT06533098 (A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06533098)) |
| Dec 2027 to Mar 2028 | [Iti-1284 10 mg topline data readout](https://sec-api.dev/pdufa/iti-1284) | JNJ | Agitation Associated With Alzheimer's Dementia | scheduled | "NCT06651567 (A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06651567)) |
| Dec 2027 to Mar 2028 | [RYBREVANT (amivantamab) topline data readout](https://sec-api.dev/pdufa/amivantamab) | JNJ | Colorectal Neoplasms | scheduled | "NCT06750094 (A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750094)) |
| Dec 2027 to Mar 2028 | [Ramantamig topline data readout](https://sec-api.dev/pdufa/ramantamig) | JNJ | Multiple Myeloma | scheduled | "NCT07589634 (A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07589634)) |
| December 2027 | [Imbruvica (ibrutinib) primary completion](https://sec-api.dev/pdufa/ibrutinib) | JNJ | Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Lymphoma | scheduled | "NCT05963074 (A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05963074)) |
| December 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Thrombocytopenia, Neonatal Alloimmune | scheduled | "NCT06533098 (A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06533098)) |
| December 2027 | [RYBREVANT (amivantamab) primary completion](https://sec-api.dev/pdufa/amivantamab) | JNJ | Colorectal Neoplasms | scheduled | "NCT06750094 (A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750094)) |
| December 2027 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Agitation Associated With Alzheimer's Dementia | scheduled | "NCT06651567 (A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06651567)) |
| December 2027 | [Ramantamig primary completion](https://sec-api.dev/pdufa/ramantamig) | JNJ | Multiple Myeloma | scheduled | "NCT07589634 (A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07589634)) |
| Jan to Apr 2028 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Colitis, Ulcerative | scheduled | "NCT07196748 (A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196748)) |
| January 2028 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Colitis, Ulcerative | scheduled | "NCT07196748 (A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196748)) |
| Feb to May 2028 | [JNJ-101556143 topline data readout](https://sec-api.dev/pdufa/jnj-101556143) | JNJ | Prostatic Neoplasms | scheduled | "NCT07906717 (A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07906717)) |
| February 2028 | [JNJ-101556143 primary completion](https://sec-api.dev/pdufa/jnj-101556143) | JNJ | Prostatic Neoplasms | scheduled | "NCT07906717 (A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07906717)) |
| Mar to Jun 2028 | [Lazcluze (lazertinib mesylate) topline data readout](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT07586202 (A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07586202)) |
| March 2028 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT07586202 (A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07586202)) |
| Apr to Jul 2028 | [Gemzar (gemcitabine) topline data readout](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Non-Muscle Invasive Bladder Neoplasms | scheduled | "NCT06919965 (A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-06 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06919965)) |
| Apr to Jul 2028 | [Cilta-cel topline data readout](https://sec-api.dev/pdufa/cilta-cel) | JNJ | Multiple Myeloma | scheduled | "NCT07149857 (A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07149857)) |
| April 2028 | [Gemzar (gemcitabine) primary completion](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Non-Muscle Invasive Bladder Neoplasms | scheduled | "NCT06919965 (A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-06 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06919965)) |
| April 2028 | [Cilta-cel primary completion](https://sec-api.dev/pdufa/cilta-cel) | JNJ | Multiple Myeloma | scheduled | "NCT07149857 (A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-04-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07149857)) |
| Jun to Sep 2028 | [Jnj-90301900 (nbtxr3) topline data readout](https://sec-api.dev/pdufa/jnj-90301900-nbtxr3) | JNJ | Carcinoma, Squamous Cell | scheduled | "NCT04892173 (JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Johnson & Johnson Enterprise Innovation Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04892173)) |
| Jun to Sep 2028 | [Gemzar (gemcitabine) topline data readout](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Non-Muscle Invasive Bladder Neoplasms | scheduled | "NCT06319820 (A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06319820)) |
| Jun to Sep 2028 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn Disease | scheduled | "NCT07577843 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07577843)) |
| June 2028 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn Disease | scheduled | "NCT07577843 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07577843)) |
| June 2028 | [Gemzar (gemcitabine) primary completion](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Non-Muscle Invasive Bladder Neoplasms | scheduled | "NCT06319820 (A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06319820)) |
| June 2028 | [Jnj-90301900 (nbtxr3) primary completion](https://sec-api.dev/pdufa/jnj-90301900-nbtxr3) | JNJ | Carcinoma, Squamous Cell | scheduled | "NCT04892173 (JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Johnson & Johnson Enterprise Innovation Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04892173)) |
| Aug to Nov 2028 | [JNJ-87189401 topline data readout](https://sec-api.dev/pdufa/jnj-87189401) | JNJ | Metastatic Castration-resistant Prostatic Neoplasms | scheduled | "NCT07164443 (A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-18 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07164443)) |
| Aug to Nov 2028 | [Seltorexant topline data readout](https://sec-api.dev/pdufa/seltorexant) | JNJ | Depressive Disorder, Major | scheduled | "NCT07573176 (A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-24 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07573176)) |
| Aug to Nov 2028 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Colitis, Ulcerative | scheduled | "NCT07577856 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07577856)) |
| August 2028 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Colitis, Ulcerative | scheduled | "NCT07577856 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07577856)) |
| August 2028 | [JNJ-87189401 primary completion](https://sec-api.dev/pdufa/jnj-87189401) | JNJ | Metastatic Castration-resistant Prostatic Neoplasms | scheduled | "NCT07164443 (A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-18 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07164443)) |
| August 2028 | [Seltorexant primary completion](https://sec-api.dev/pdufa/seltorexant) | JNJ | Depressive Disorder, Major | scheduled | "NCT07573176 (A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-24 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07573176)) |
| Sep to Dec 2028 | [Iti-1284 10 mg topline data readout](https://sec-api.dev/pdufa/iti-1284) | JNJ | Psychotic Disorders; Alzheimer Disease | scheduled | "NCT06540833 (A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-30 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06540833)) |
| Sep to Dec 2028 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Crohn Disease | scheduled | "NCT07196722 (A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196722)) |
| September 2028 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Crohn Disease | scheduled | "NCT07196722 (A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196722)) |
| September 2028 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Psychotic Disorders; Alzheimer Disease | scheduled | "NCT06540833 (A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-30 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06540833)) |
| Nov 2028 to Feb 2029 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn Disease | scheduled | "NCT07499232 (A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07499232)) |
| November 2028 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Crohn Disease | scheduled | "NCT07499232 (A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07499232)) |
| Dec 2028 to Mar 2029 | [RYBREVANT (amivantamab) topline data readout](https://sec-api.dev/pdufa/amivantamab) | JNJ | Colorectal Neoplasms | scheduled | "NCT06662786 (A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06662786)) |
| Dec 2028 to Mar 2029 | [JNJ-90301900 topline data readout](https://sec-api.dev/pdufa/jnj-90301900) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06667908 (A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Johnson & Johnson Enterprise Innovation Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06667908)) |
| Dec 2028 to Mar 2029 | [JNJ-79635322 topline data readout](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07258511 (A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07258511)) |
| Dec 2028 to Mar 2029 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Lupus Erythematosus, Systemic | scheduled | "NCT07438496 (A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-06 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07438496)) |
| Dec 2028 to Mar 2029 | [Spravato (esketamine hydrochloride) topline data readout](https://sec-api.dev/pdufa/esketamine) | JNJ | Depressive Disorder, Treatment-Resistant | scheduled | "NCT07716098 (A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-27 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07716098)) |
| December 2028 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Lupus Erythematosus, Systemic | scheduled | "NCT07438496 (A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-06 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07438496)) |
| December 2028 | [JNJ-79635322 primary completion](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07258511 (A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-12 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07258511)) |
| December 2028 | [RYBREVANT (amivantamab) primary completion](https://sec-api.dev/pdufa/amivantamab) | JNJ | Colorectal Neoplasms | scheduled | "NCT06662786 (A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06662786)) |
| December 2028 | [Spravato (esketamine hydrochloride) primary completion](https://sec-api.dev/pdufa/esketamine) | JNJ | Depressive Disorder, Treatment-Resistant | scheduled | "NCT07716098 (A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-27 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07716098)) |
| December 2028 | [JNJ-90301900 primary completion](https://sec-api.dev/pdufa/jnj-90301900) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06667908 (A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Johnson & Johnson Enterprise Innovation Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06667908)) |
| Jan to Apr 2029 | [DARZALEX (daratumumab) topline data readout](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT05438043 (A Study of Daratumumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05438043)) |
| January 2029 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT05438043 (A Study of Daratumumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05438043)) |
| Feb to May 2029 | [Revlimid® (lenalidomide) topline data readout](https://sec-api.dev/pdufa/lenalidomide) | JNJ | Multiple Myeloma | scheduled | "NCT04923893 (A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04923893)) |
| February 2029 | [Revlimid® (lenalidomide) primary completion](https://sec-api.dev/pdufa/lenalidomide) | JNJ | Multiple Myeloma | scheduled | "NCT04923893 (A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04923893)) |
| Apr to Jul 2029 | [JNJ-79635322 topline data readout](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07518186 (A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-29 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07518186)) |
| April 2029 | [JNJ-79635322 primary completion](https://sec-api.dev/pdufa/jnj-79635322) | JNJ | Multiple Myeloma | scheduled | "NCT07518186 (A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-29 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07518186)) |
| May to Aug 2029 | [Lazcluze (lazertinib mesylate) topline data readout](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06667076 (A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-23 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06667076)) |
| May to Aug 2029 | [JNJ-101556143 topline data readout](https://sec-api.dev/pdufa/jnj-101556143) | JNJ | Prostatic Neoplasms | scheduled | "NCT07832292 (A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07832292)) |
| May 2029 | [JNJ-101556143 primary completion](https://sec-api.dev/pdufa/jnj-101556143) | JNJ | Prostatic Neoplasms | scheduled | "NCT07832292 (A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07832292)) |
| May 2029 | [Lazcluze (lazertinib mesylate) primary completion](https://sec-api.dev/pdufa/lazertinib) | JNJ | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT06667076 (A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-23 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06667076)) |
| Jun to Sep 2029 | [Bleximenib topline data readout](https://sec-api.dev/pdufa/bleximenib) | JNJ | Leukemia, Myeloid, Acute | scheduled | "NCT06852222 (A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-22 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06852222)) |
| Jun to Sep 2029 | [RYBREVANT (amivantamab) topline data readout](https://sec-api.dev/pdufa/amivantamab) | JNJ | Squamous Cell Carcinoma of Head and Neck | scheduled | "NCT07276399 (A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-18 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276399)) |
| June 2029 | [RYBREVANT (amivantamab) primary completion](https://sec-api.dev/pdufa/amivantamab) | JNJ | Squamous Cell Carcinoma of Head and Neck | scheduled | "NCT07276399 (A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-18 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276399)) |
| June 2029 | [Bleximenib primary completion](https://sec-api.dev/pdufa/bleximenib) | JNJ | Leukemia, Myeloid, Acute | scheduled | "NCT06852222 (A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-22 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06852222)) |
| Aug to Nov 2029 | [Erleada (apalutamide) topline data readout](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT04557059 (A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-27 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04557059)) |
| Aug to Nov 2029 | [JNJ-81201887 topline data readout](https://sec-api.dev/pdufa/jnj-81201887) | JNJ | Geographic Atrophy; Macular Degeneration | scheduled | "NCT06635148 (A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-24 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635148)) |
| August 2029 | [JNJ-81201887 primary completion](https://sec-api.dev/pdufa/jnj-81201887) | JNJ | Geographic Atrophy; Macular Degeneration | scheduled | "NCT06635148 (A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-24 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635148)) |
| August 2029 | [Erleada (apalutamide) primary completion](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT04557059 (A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-27 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04557059)) |
| Sep to Dec 2029 | [TAR-200 topline data readout](https://sec-api.dev/pdufa/tar-200) | JNJ | Bladder Cancer | scheduled | "NCT05714202 (A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-09-18 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05714202)) |
| Sep to Dec 2029 | [JNJ-95597528 topline data readout](https://sec-api.dev/pdufa/jnj-95597528) | JNJ | Asthma | scheduled | "NCT07746687 (A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-09-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07746687)) |
| Sep to Dec 2029 | [Caplyta (lumateperone tosylate) topline data readout](https://sec-api.dev/pdufa/lumateperone) | JNJ | Depressive Disorder, Major | scheduled | "NCT07747389 (A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-09-20 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07747389)) |
| September 2029 | [JNJ-95597528 primary completion](https://sec-api.dev/pdufa/jnj-95597528) | JNJ | Asthma | scheduled | "NCT07746687 (A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-09-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07746687)) |
| September 2029 | [TAR-200 primary completion](https://sec-api.dev/pdufa/tar-200) | JNJ | Bladder Cancer | scheduled | "NCT05714202 (A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-09-18 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05714202)) |
| September 2029 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Depressive Disorder, Major | scheduled | "NCT07747389 (A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-09-20 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07747389)) |
| Dec 2029 to Mar 2030 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Thrombocytopenia, Neonatal Alloimmune | scheduled | "NCT06449651 (A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-05 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06449651)) |
| December 2029 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Thrombocytopenia, Neonatal Alloimmune | scheduled | "NCT06449651 (A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-05 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06449651)) |
| Feb to May 2030 | [Iti-1284 10 mg topline data readout](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT07807865 (A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-18 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07807865)) |
| February 2030 | [Iti-1284 10 mg primary completion](https://sec-api.dev/pdufa/iti-1284) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT07807865 (A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-18 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07807865)) |
| May to Aug 2030 | [Talquetamab topline data readout](https://sec-api.dev/pdufa/talquetamab) | JNJ | Multiple Myeloma | scheduled | "NCT06500884 (A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06500884)) |
| May 2030 | [Talquetamab primary completion](https://sec-api.dev/pdufa/talquetamab) | JNJ | Multiple Myeloma | scheduled | "NCT06500884 (A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06500884)) |
| Sep to Dec 2030 | [DARZALEX (daratumumab) topline data readout](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT06577025 (A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06577025)) |
| Sep to Dec 2030 | [DARZALEX (daratumumab) topline data readout](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT07665450 (A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-04 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07665450)) |
| Sep to Dec 2030 | [JNJ-99245354 topline data readout](https://sec-api.dev/pdufa/jnj-99245354) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT07856420 (A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-20 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07856420)) |
| September 2030 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT06577025 (A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-09-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06577025)) |
| September 2030 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | scheduled | "NCT07665450 (A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-04 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07665450)) |
| September 2030 | [JNJ-99245354 primary completion](https://sec-api.dev/pdufa/jnj-99245354) | JNJ | Generalized Anxiety Disorder | scheduled | "NCT07856420 (A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-20 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07856420)) |

## Drugs

- [Akeega (abiraterone acetate; niraparib tosylate)](https://sec-api.dev/pdufa/abiraterone-niraparib): 
- [RYBREVANT (amivantamab)](https://sec-api.dev/pdufa/amivantamab): Squamous Cell Carcinoma of Head and Neck, Colorectal Neoplasms
- [Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)](https://sec-api.dev/pdufa/amivantamab-and-hyaluronidase-lpuj): 
- [Rybrevant (amivantamab-vmjw)](https://sec-api.dev/pdufa/amivantamab-vmjw): 
- [Erleada (apalutamide)](https://sec-api.dev/pdufa/apalutamide): Metastatic Castrate-sensitive Prostate Cancer, Prostatic Neoplasms
- [Sirturo (bedaquiline fumarate)](https://sec-api.dev/pdufa/bedaquiline): 
- [Bedaquiline (tmc207)](https://sec-api.dev/pdufa/bedaquiline-tmc207): Tuberculosis, Multidrug-Resistant
- [Bleximenib](https://sec-api.dev/pdufa/bleximenib): Leukemia, Myeloid, Acute
- [Tracleer (bosentan)](https://sec-api.dev/pdufa/bosentan): 
- [Invokana (canagliflozin)](https://sec-api.dev/pdufa/canagliflozin): 
- [Invokamet Xr (canagliflozin; metformin hydrochloride)](https://sec-api.dev/pdufa/canagliflozin-metformin): 
- [Cilta-cel](https://sec-api.dev/pdufa/cilta-cel): Multiple Myeloma
- [CARVYKTI (ciltacabtagene autoleucel)](https://sec-api.dev/pdufa/ciltacabtagene-autoleucel): with relapsed or refractory multiple myeloma, with rrmm
- [Prezcobix (cobicistat; darunavir and cobicistat; darunavir ethanolate)](https://sec-api.dev/pdufa/cobicistat-darunavir-and-cobicistat-darunavir-ethanolate): 
- [Symtuza (cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate)](https://sec-api.dev/pdufa/cobicistat-darunavir-emtricitabine-tenofovir-alafenamide): 
- [Prezcobix (cobicistat; darunavir ethanolate)](https://sec-api.dev/pdufa/cobicistat-darunavir-ethanolate): 
- [DARZALEX (daratumumab)](https://sec-api.dev/pdufa/daratumumab): Multiple Myeloma, Amyloidosis
- [Darzalex Faspro (daratumumab and hyaluronidase-fihj)](https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj): 
- [Balversa (erdafitinib)](https://sec-api.dev/pdufa/erdafitinib): 
- [Spravato (esketamine hydrochloride)](https://sec-api.dev/pdufa/esketamine): Depressive Disorder, Treatment-Resistant
- [Expec9v](https://sec-api.dev/pdufa/expec9v): Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
- [Gemzar (gemcitabine)](https://sec-api.dev/pdufa/gemcitabine): Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms
- [Aria® (golimumab)](https://sec-api.dev/pdufa/golimumab): with inflammatory conditions, moderate to severe rheumatoid arthritis, variety of inflammatory conditions
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab): Crohn's Disease, Crohn Disease, Colitis, Ulcerative, Fistulizing Crohns Disease, Plaque Psoriasis
- [Guselkumab subcutaneous](https://sec-api.dev/pdufa/guselkumab-subcutaneous): Colitis, Ulcerative
- [ICOTYDE (icotrokinra)](https://sec-api.dev/pdufa/icotrokinra): moderately-to-severely active ulcerative colitis, moderately-to-severely active uc, moderately to severely active ulcerative colitis, moderately to severely active ulcerative colitis3, Arthritis, Psoriatic, Colitis, Ulcerative, Crohn Disease
- [Iti-1284 10 mg](https://sec-api.dev/pdufa/iti-1284): Agitation Associated With Alzheimer's Dementia, Generalized Anxiety Disorder, Psychotic Disorders
- [JNJ-101556143](https://sec-api.dev/pdufa/jnj-101556143): Prostatic Neoplasms
- [JNJ-63733657](https://sec-api.dev/pdufa/jnj-63733657): Alzheimer Disease
- [JNJ-64042056](https://sec-api.dev/pdufa/jnj-64042056): Alzheimer Disease
- [JNJ-79635322](https://sec-api.dev/pdufa/jnj-79635322): Multiple Myeloma
- [JNJ-81201887](https://sec-api.dev/pdufa/jnj-81201887): Geographic Atrophy
- [JNJ-87189401](https://sec-api.dev/pdufa/jnj-87189401): Metastatic Castration-resistant Prostatic Neoplasms
- [JNJ-88545223](https://sec-api.dev/pdufa/jnj-88545223): Arthritis, Psoriatic
- [JNJ-89495120](https://sec-api.dev/pdufa/jnj-89495120): Depressive Disorder, Major
- [JNJ-90301900](https://sec-api.dev/pdufa/jnj-90301900): Carcinoma, Non-Small-Cell Lung
- [Jnj-90301900 (nbtxr3)](https://sec-api.dev/pdufa/jnj-90301900-nbtxr3): Carcinoma, Squamous Cell
- [JNJ-95475939](https://sec-api.dev/pdufa/jnj-95475939): Dermatitis, Atopic
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528): Asthma, Dermatitis, Atopic
- [JNJ-99245354](https://sec-api.dev/pdufa/jnj-99245354): Generalized Anxiety Disorder
- [Acuvue Theravision With Ketotifen (ketotifen fumarate)](https://sec-api.dev/pdufa/ketotifen): 
- [Lazcluze (lazertinib mesylate)](https://sec-api.dev/pdufa/lazertinib): To treat non-small cell lung cancer, Carcinoma, Non-small-Cell Lung
- [Revlimid® (lenalidomide)](https://sec-api.dev/pdufa/lenalidomide): Multiple Myeloma
- [Lenrispodun](https://sec-api.dev/pdufa/lenrispodun): Parkinson Disease
- [Caplyta (lumateperone tosylate)](https://sec-api.dev/pdufa/lumateperone): Depressive Disorder, Major, Major Depressive Disorder, Bipolar Disorder, Manic, Irritability Associated With Autism Spectrum Disorder
- [Opsumit (macitentan)](https://sec-api.dev/pdufa/macitentan): Pulmonary Arterial Hypertension, Hypertension, Pulmonary
- [Opsynvi (macitentan; tadalafil)](https://sec-api.dev/pdufa/macitentan-tadalafil): 
- [Vermox (mebendazole)](https://sec-api.dev/pdufa/mebendazole): 
- [Milvexian](https://sec-api.dev/pdufa/milvexian): Ischemic Stroke; Ischemic Attack, Transient, Atrial Fibrillation, Acute Coronary Syndrome
- [IMAAVY (nipocalimab)](https://sec-api.dev/pdufa/nipocalimab): Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Thrombocytopenia, Neonatal Alloimmune, Hemolytic Disease of the Fetus and Newborn, Myasthenia Gravis, Lupus Erythematosus, Systemic, Myositis, Sjogrens Syndrome
- [Imaavy (nipocalimab-aahu)](https://sec-api.dev/pdufa/nipocalimab-aahu): To treat generalized myasthenia gravis
- [Invega Hafyera (paliperidone palmitate)](https://sec-api.dev/pdufa/paliperidone-palmitate): 
- [Pasritamig](https://sec-api.dev/pdufa/pasritamig): Prostatic Neoplasms, Castration-Resistant
- [Pipe-307 dose a](https://sec-api.dev/pdufa/pipe-307): relapsing-remitting multiple sclerosis, rrms, referred to, Relapsing Remitting Multiple Sclerosis
- [Ramantamig](https://sec-api.dev/pdufa/ramantamig): Multiple Myeloma
- [Edurant Ped (rilpivirine hydrochloride)](https://sec-api.dev/pdufa/rilpivirine): Human Immunodeficiency Virus Type 1
- [Xarelto (rivaroxaban)](https://sec-api.dev/pdufa/rivaroxaban): 
- [Uptravi (selexipag)](https://sec-api.dev/pdufa/selexipag): pah, such
- [Seltorexant](https://sec-api.dev/pdufa/seltorexant): Depressive Disorder, Major
- [Talquetamab](https://sec-api.dev/pdufa/talquetamab): Hematological Malignancies, Multiple Myeloma
- [Talvey (talquetamab-tgvs)](https://sec-api.dev/pdufa/talquetamab-tgvs): 
- [TAR-200](https://sec-api.dev/pdufa/tar-200): Bladder Cancer, Urinary Bladder Neoplasms
- [TECVAYLI (teclistamab)](https://sec-api.dev/pdufa/teclistamab): with relapsed or refractory multiple myeloma, Multiple Myeloma
- [Tecvayli (teclistamab-cqyv)](https://sec-api.dev/pdufa/teclistamab-cqyv): 
- [Topamax Sprinkle (topiramate)](https://sec-api.dev/pdufa/topiramate): 
- [WEZLANA® (ustekinumab)](https://sec-api.dev/pdufa/ustekinumab): Plaque Psoriasis, Crohn Disease, Arthritis, Juvenile
- [Ustekinumab dose based on bsa and body weight](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight): Colitis, Ulcerative

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/jnj/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "JNJ catalysts: JOHNSON & JOHNSON PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/jnj/catalysts

```bibtex
@misc{secapidev_companies_jnj_catalysts_20261116,
  title        = {JNJ catalysts: JOHNSON & JOHNSON PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/jnj/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_jnj_catalysts_20261116","title":"JNJ catalysts: JOHNSON & JOHNSON PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/jnj/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
